The honest answer to the question organizations keep asking — which poses the greater risk, artificial intelligence or biology? — is that the two can no longer be separated. In 2026, the US government acted on exactly that premise: a July White House policy now defines and restricts "Dangerous Gain-of-Function" research while simultaneously creating an interagency group to monitor AI's use in the life sciences. Congress, meanwhile, has three pending bills that treat biosecurity and AI safeguards as complementary rather than competing concerns. The policy momentum is real; the expert consensus on AI's current capabilities is more sober than the headlines suggest.
Introduction: The Converging Threats of AI and Biology
The core of the 2026 debate is a convergence problem. As the World Economic Forum frames it, the combination of AI-enabled biology, climate change, and global mobility means "the gap between emergence and impact is closing rapidly, while our systems for surveillance, attribution and response are struggling to keep pace." Natural biosecurity hazards remain more likely than manmade ones, in that assessment, but the threat from intentionally released pathogens is rising. The reason is accessibility: laboratory tools and computing power are now widely enough available that, in principle, a technically capable individual could design organisms capable of disrupting human health, agriculture, or ecosystems. That is the backdrop against which every 2026 US policy move should be read.
